Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology,European Journal of Heart Failure

当前位置： X-MOL 学术 › Eur. J. Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2022-06-15 , DOI: 10.1002/ejhf.2575
Peter Seferović _{1,

2} , Dimitrios Farmakis ₃ , Antoni Bayes-Genis _{4,

5,

6} , Tuvia Ben Gal ₇ , Michael Böhm ₈ , Ovidiu Chioncel ₉ , Roberto Ferrari _{10,

11} , Gerasimos Filippatos ₁₂ , Loreena Hill ₁₃ , Ewa Jankowska _{14,

15} , Mitja Lainscak ₁₆ , Yuri Lopatin ₁₇ , Lars H Lund ₁₈ , Alexandre Mebazaa ₁₉ , Marco Metra ₂₀ , Brenda Moura ₂₁ , Giuseppe Rosano _{22,

23} , Thomas Thum _{24,

25,

26} , Adriaan Voors ₂₇ , Andrew J S Coats ₂₈

Affiliation

Faculty of Medicine, University of Belgrade Belgrade, Serbia and Serbian Academy of Sciences and Arts, Belgrade, Serbia.
University of Belgrade Belgrade, Belgrade, Serbia.
University of Cyprus Medical School, Nicosia, Cyprus.
Heart Institute, Hospital Universitari German Trias i Pujol, Badalona, Spain.
Department of Medicine, Universitat Autónoma de Barcelona, Barcelona, Spain.
CIBERCV, Instituto de Salud, Madrid, Spain.
Heart Failure Unit, Cardiology Department, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg, Germany.
Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, and University of Medicine Carol Davila, Bucharest, Romania.
Maria Cecilia Hospital, GVM Care & Research, Ravenna, Italy.
Laboratory for Technologies of Advanced Therapies (LTTA), Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Second Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrina University of Athens Medical School, Athens, Greece.
School of Nursing and Midwifery, Queen's University, Belfast, UK.
Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Centre for Heart Diseases, University Hospital, Wroclaw, Poland.
Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Volgograd State Medical University, Regional Cardiology Centre Volgograd, Volgograd, Russian Federation.
Department of Medicine, Karolinska Institutet, and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
INSERM UMR-S 942, Paris, France; Department of Anesthesiology and Critical Care Medicine, St. Louis and Lariboisère University Hospitals, Paris, France.
Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
CINTESIS - Centro de Investigação em Tecnologias e Serviços de Saúde, Porto, Portugal; Serviço de Cardiologia, Hospital das Forças Armadas - Pólo do Porto, Porto, Portugal.
Cardiovascular Clinical Academic Group, St George's Hospitals NHS Trust University of London, London, UK.
IRCCS San Raffaele Pisana, Rome, Italy.
Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.
REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany.
Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.
Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Warwick Medical School, University of Warwick, Coventry, UK.

Knowledge on risk predictors of incident heart failure (HF) in patients with type 2 diabetes (T2D) is crucial given the frequent coexistence of the two conditions and the fact that T2D doubles the risk of incident HF. In addition, HF is increasingly being recognized as an important endpoint in trials in T2D. On the other hand, the diagnostic and prognostic performance of established cardiovascular biomarkers may be modified by the presence of T2D. The present position paper, derived by an expert panel workshop organized by the Heart Failure Association of the European Society of Cardiology, summarizes the current knowledge and gaps in evidence regarding the use of a series of different biomarkers, reflecting various pathogenic pathways, for the prediction of incident HF and cardiovascular events in patients with T2D and in those with established HF and T2D.

中文翻译：

预测 2 型糖尿病患者心力衰竭和心血管事件的生物标志物：欧洲心脏病学会心力衰竭协会的立场声明

鉴于 2 型糖尿病 (T2D) 患者频繁并存心力衰竭 (HF) 以及 T2D 使心力衰竭风险加倍这一事实，了解 2 型糖尿病 (T2D) 患者发生心力衰竭 (HF) 的风险预测因素至关重要。此外，HF 越来越多地被认为是 T2D 试验中的一个重要终点。另一方面，已建立的心血管生物标志物的诊断和预后性能可能会因 T2D 的存在而改变。本立场文件由欧洲心脏病学会心力衰竭协会组织的专家小组研讨会得出，总结了关于使用一系列不同生物标志物的当前知识和证据差距，反映了各种致病途径，

更新日期：2022-06-15

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11